Skip Navigation


Annals of Oncology Advance Access originally published online on December 21, 2006
Annals of Oncology 2007 18(4):665-671; doi:10.1093/annonc/mdl458
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/4/665    most recent
mdl458v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Montemurro, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Montemurro, M
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

hematologic malignancies

Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hämato-Onkologie OSHO-53 phase II study

M Montemurro1,{dagger}, T Kiefer1, F Schüler1, HK Al-Ali2, H-H Wolf3, R Herbst4, A Haas5, K Helke6, A Theilig7, C Lotze1, C Hirt1, D Niederwieser2, M Schwenke1,8, WH Krüger1,{dagger}, G Dölken1,* For the Ostdeutsche Studiengruppe Hämatologie und Onkologie

1 Department of Internal Medicine C, Hematology and Oncology, Stem Cell Transplantation, Ernst-Moritz-Arndt-University, Greifswald, Germany
2 Division of Hematology and Oncology, University of Leipzig, Leipzig
3 Department of Internal Medicine IV, Hematology and Oncology, Martin-Luther-University Halle-Wittenberg, Halle/Saale
4 Department of Hematology-Oncology-Bone Marrow Transplantation, Chemnitz Hospital, Chemnitz
5 Department of Internal Medicine, Hematology and Oncology, Hospital Ernst-von-Bergmann, Potsdam
6 Department of Radiotherapy, Ernst-Moritz-Arndt-University, Greifswald
7 Department of Neurology, Ernst-Moritz-Arndt-University, Greifswald
8 Department of Internal Medicine, BFA-Hospital Ückeritz, Ückeritz, Germany

* Correspondence to: Prof. Dr G. Dölken, Ernst-Moritz-Arndt-Universität Greifswald, Klinik und Poliklinik für Innere Medizin C, Hämatologie und Onkologie—Transplantationszentrum, Sauerbruchstraße, 17475 Greifswald. Tel: +49-3834-866698; Fax +49-3834-866713; E-mail: michael.montemurro{at}chuv.ch

Background: We investigated the efficacy and safety of tandem high-dose methotrexate (HD-MTX) induction followed by high-dose busulfan/thiotepa (HD-BuTT) with autologous peripheral blood stem-cell transplantation (aPBSCT) and response-adapted whole-brain radiation therapy (WBRT) in patients with newly diagnosed primary central nervous system lymphoma.

Patients and methods: Twenty-three patients were treated with HD-MTX on days 1 and 10. In case of at least a partial remission (PR), HD-BuTT followed by aPBSCT was given. Patients without response to induction or without complete remission (CR) after HD-BuTT received WBRT.

Results: Sixteen patients received HD-MTX and HD-BuTT achieving a CR/PR rate of 69%/13%. CR/PR rates for all patients (n = 23) were 70%/13%. There were three deaths during therapy. With longer follow-up three neurotoxic deaths occurred in irradiated patients (n = 9), while no persistent neurotoxicity was seen after HD-BuTT without subsequent WBRT. At a median follow-up of 15 months (range 1–69) median event-free survival (EFS) and overall survival (OS) for all patients were 17 and 20 months (Kaplan–Meier), after HD-BuTT 27 months and ‘not reached’, respectively. Estimated 2-year EFS and OS were 45% and 48% for all patients versus 56% and 61% for the HD-BuTT group, respectively.

Conclusion: MTX induction followed by HD-BuTT is an effective and very short time-on-treatment regimen. Median survival for patients treated with high-dose chemotherapy is not reached yet. The induction regimen needs optimisation. In this study WBRT was associated with a high incidence of severe neurotoxicity.

Key words: autologous stem-cell transplantation, CNS lymphoma, high-dose chemotherapy, methotrexate, neurotoxicity, PCNSL

{dagger} These authors contributed equally to the paper.

Received for publication May 13, 2006. Revision received October 18, 2006. Accepted for publication October 25, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
C. Soussain, K. Hoang-Xuan, L. Taillandier, E. Fourme, S. Choquet, F. Witz, O. Casasnovas, B. Dupriez, B. Souleau, A.-L. Taksin, et al.
Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire
J. Clin. Oncol., May 20, 2008; 26(15): 2512 - 2518.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
G. Illerhaus, F. Muller, F. Feuerhake, A.-O. Schafer, C. Ostertag, and J. Finke
High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system
Haematologica, January 1, 2008; 93(1): 147 - 148.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.